ENOV ENOVIS CORPORATION

Enovis Showcases New Foot & Ankle Offerings at the ACFAS Annual Meeting

Enovis Showcases New Foot & Ankle Offerings at the ACFAS Annual Meeting

New solutions in Percutaneous and Open Bunion procedures, External Fixation, and STAR® Ankle will be featured as part of the company’s growing evidence-based, innovative portfolio.

WILMINGTON, DE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Today, Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced it will showcase the latest technologies from its Global Foot and Ankle business at the American College of Foot & Ankle (ACFAS) annual meeting in Tampa, Fla., from February 1-4, 2024. The company will feature products from its recent acquisitions of Novastep® and the external fixation assets of D.N.E., LLC, along with the internally developed Evolve34™ Lapidus Correction System, and the STAR+ Experience with Patient Specific Instrumentation.

“With a commitment to advancing technology and improving user experience, we are proud to share our newest technologies at this year’s meeting,” stated Gary Justak, President and General Manager of Enovis™ Foot and Ankle. “Our recent acquisition of Novastep® and the Pecaplasty® Percutaneous Bunion Correction System will drive outcome improvements with an underserved patient population, and the MIS bunion surgery provides efficiency in the OR for the surgeon, while improving patient recovery times with less pain.1,2,3”

Being showcased at ACFAS for the first time will be Evolve34™, a bunion solution for Lapidus correction that allows surgeons to dial in deformity correction and select a hardware construct specific for the patient’s needs. Additionally, Enovis will be introducing the all new EF1 External Fixation product line, complimenting the flagship DynaNail® and DynaClip™ offerings in the hindfoot segment.

Enovis will also highlight products from its foot and ankle continuum of care, including the following products from its subsidiary DJO, LLC:

  • Walking Boot
  • A versatile stirrup design that aids in the treatment of posterior tibial tendon dysfunction (PTTD)
  • Bone Stimulation Device

In addition, visitors can request samples of two new, upcoming Enovis Foot & Ankle products:

  • Arsenal Foot Plating – Booth visitors can see recent updates including technologies from the company’s Arsenal Ankle Plating System such as Type II Anodization and lower profile plating.
  • Tiger Cannulated Screw System - The revamped Tiger Cannulated Screw System includes an updated hexalobe head and size variations that booth visitors can ask to see.

ACFAS attendees have opportunities throughout the week to experience these product offerings firsthand at Booth #601, along with the following events:

  • Enovis Lab at ACFAS – “Transforming Lapidus Correction Surgery: Modern Techniques & Innovations.” Experience the powerful correction, predictable results, and procedural flexibility of Evolve34™ Lapidus Correction System during this sawbones lab on Thursday, February 1 from 1:30-2:30 p.m. This is part of the ACFAS Innovation Lab right on the Exhibit Floor at the back of the 1100 aisle. Register here: 
  • Enovis Customer Event – “The Foot & Ankle Experience.” Join us at the Tampa Aquarium Rooftop Terrace on Friday, February 2 from 5:30 p.m. - 8:00 p.m. and take a deep dive into Enovis' latest offerings from percutaneous bunion solutions to Lapidus specific solutions, external fixation and more. Register here:





About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit .



  1. Lee M, Walsh J, Smith MM, Ling J, Wines A, Lam P. Hallux valgus correction comparing percutaneous chevron/Akin (PECA) and open scarf/Akin osteotomies. Foot Ankle Int. 2017;38(8):838-846. doi:10.1177/1071100717704941
  2. Maffulli N, Longo UG, Oliva F, Denaro V, Coppola C. Bosch osteotomy and scarf osteotomy for hallux valgus correction. Orthop Clin North Am. 2009;40(4):515-524. doi:10.1016/j.ocl.2009.06.003
  3. Lam P, Lee M, Xing J, Di Nallo M. Percutaneous surgery for mild to moderate hallux valgus. Foot Ankle Clin. 2016;21(3):459-477. doi:10.1016/j.fcl.2016.04.001





Media Contact:

Megan Foltz Nayak

609-680-0996

Attachment



Media Contact:
Megan Foltz Nayak
609-680-0996
 
EN
29/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13th at 8:30 a.m. Eastern Time.Wells Fargo Healthcare Conference on Wednesday, September 3rd at 2:15 p.m. Eastern Time.Baird 2025 Global Healthcare Conference on Wednesday, September 10th at 3:10 p.m. Eastern Time. A link to the l...

 PRESS RELEASE

Enovis Announces Second Quarter 2025 Results

Enovis Announces Second Quarter 2025 Results Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2...

 PRESS RELEASE

Enovis to Host Second Quarter 2025 Results Conference Call on August 7...

Enovis to Host Second Quarter 2025 Results Conference Call on August 7th Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at . Conference C...

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th Annual Global Healthcare Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, June 10th at 2:00 p.m. Eastern Time.Citizens Medical Devices and Healthcare Services Forum: Ben Berry, Chief Financial Officer, will participate in investor meet...

 PRESS RELEASE

Enovis Announces First Quarter 2025 Results

Enovis Announces First Quarter 2025 Results Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch